Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alfentanil is a synthetic, short-acting opioid analgesic and anesthetic, classified as a small-molecule derivative of fentanyl. It acts as an agonist at the μ-opioid receptor, producing potent analgesia and sedation by binding to stereospecific receptors in the central nervous system. Alfentanil is characterized by its rapid onset (four times faster than fentanyl) and short duration of action (one-third that of fentanyl), making it suitable for use during surgical procedures requiring quick but not long-lasting pain control. Its primary indications are as an adjunct or primary agent for anesthesia during surgery, including cardiac surgery, and for monitored anesthesia care. The drug was discovered at Janssen Pharmaceutica in 1976[5][1][2][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on alfentanil.